Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-channel EMG Mapping for Botox in Cervical Dystonia
NCT00773253Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Apr 2008
- Primary completion
- Oct 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of botulinum toxin type A in cervical dystonia (CD) (2 arms), sponsored by University of California, San Francisco. Primary endpoints: Toronto Western Spasmodic Torticollis Rating Scale at 40 weeks and Mean Percentage Change in Total Toronto Western Spasmodic Torticollis Rating Scale at 48 weeks. Started Apr 2008; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
cervical dystonia (CD)
Beyond the preview
Go deeper on NCT00773253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00773253.